New Study Suggests Seven in Ten Adults May Be Obese Under Expanded Definition

A new study, published in JAMA Network Open, indicates that an expanded definition of obesity could mean seven out of ten adults qualify. This new framework, developed by a commission convened by The Lancet Diabetes & Endocrinology, incorporates elevated Body Mass Index (BMI) plus at least one waist-based measure, or two elevated waist-based measures with a lower BMI. The findings highlight that current prescribing rules for anti-obesity drugs, which primarily rely on BMI, may exclude many clinically obese patients while including others without clinical obesity.

Context

Obesity is a major public health issue linked to various chronic diseases, including diabetes and heart disease. Traditionally, Body Mass Index (BMI) has been the primary measure for diagnosing obesity. However, this study introduces a new framework that considers waist measurements, which may provide a more accurate assessment of obesity-related health risks.

Why it matters

This study raises significant concerns about the current criteria used to define obesity, suggesting that many individuals who are clinically obese may not receive necessary treatment. The findings could prompt healthcare professionals to reassess how they diagnose and manage obesity. A broader definition may lead to increased awareness and intervention for a larger segment of the population at risk for obesity-related health issues.

Implications

If adopted widely, the expanded definition could lead to a significant increase in the number of adults classified as obese, affecting healthcare systems and insurance coverage for obesity treatments. This shift may also influence public health policies aimed at combating obesity. Individuals previously considered healthy under the old criteria may now be identified as needing intervention, impacting their access to care.

What to watch

In the near term, healthcare providers may begin to adapt their practices based on the study's findings, potentially leading to changes in obesity treatment guidelines. The pharmaceutical industry may also respond by reevaluating eligibility criteria for anti-obesity medications. Public health campaigns may emerge to educate individuals about the new definition and its implications.